(Q26748085)

1

0 references

Miguel A Gonzalez-Gay

2

0 references

Irina Kaplan

3

0 references

Mary Boy

4

0 references

Jamie Geier

5

0 references

Zhen Luo

6

0 references

Andrea Zuckerman

7

0 references

Richard Riese

Seminars in Arthritis and Rheumatism

8

0 references

language of work or name

English

0 references

publication date

August 2016

0 references

published in

0 references

volume

46

0 references

page(s)

71-80

0 references

issue

1

0 references

cites work

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

1 reference

7 January 2021

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Inflammation modulates human HDL composition and function in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Dyslipidemia in the critically ill.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Epidemiologic aspects of lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Postsurgical reduction of serum lipoproteins: interleukin-6 and the acute-phase response

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tofacitinib versus methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Serum lipids and disease severity in children with severe meningococcal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Risk factors for cardiovascular disease in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Investigation of aPON1gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: Table 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Total cholesterol and LDL levels decrease before rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Measurement of reverse cholesterol transport pathways in humans: in vivo rates of free cholesterol efflux, esterification, and excretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study).

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Use of lipid-lowering agents in rheumatoid arthritis: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SEMARTHRIT.2016.03.004

7 January 2021